Grammidin neo

Phase 1Small molecule

VValenta Pharm JSC

Grammidin neo is one of 17 small molecule programs targeting Pharyngitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PharyngitisRecruiting

PharyngitisPhase 1

Recruiting

Competition

Competitive Landscape

17 competitors in Pharyngitis

#DrugCompanyPhaseTrials

Voltaren

Novartis

Approved

1 2

Bayer Aspirin

Biaxin

Ketek

Anjeso

2 6

Ketalar

AAultman Health Foundation

Approved

—7

Bextra

TThe Searle Company Limited Pakistan

Xylocaine

Advil

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Study completion

NCT06859281

Phase 1Recruiting

Study completion

NCT06857890

Phase 2Recruiting

Pharyngeal Diseases

NCT06843018

Clinical

Trials by Indication[1]

Pharyngeal Diseases1 trial

Study to Evaluate the Efficacy and Safety of Different Doses of Graminidin With Anesthetic, a Metered Dose Topical Spray, in the Treatment of Acute Infectious and Inflammatory Pharyngeal Diseases Compared With Drug Septolete Total, Lozenges

Recruiting·VValenta Pharm JSC·Phase 2·NCT06843018·300 enrolled

Unspecified2 trials

Safety, Tolerability, and Pharmacokinetic Profile of Grammidin, a Metered Dose Topical Spray in Healthy Volunteers

Recruiting·VValenta Pharm JSC·Phase 1·NCT06859281·24 enrolled

Safety, Tolerability, and Pharmacokinetic Profile of Grammidin With Anesthetic, a Metered Dose Topical Spray in Healthy Volunteers

Recruiting·VValenta Pharm JSC·Phase 1·NCT06857890·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Grammidin neo. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Grammidin neo compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Grammidin neo. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Valenta Pharm JSC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: VValenta Pharm JSC

Grammidin neo

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Pharyngeal Diseases1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News